In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19.